Idarucizumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Idarucizumab" in English language version.

refsWebsite

Global rank English rank

8nih.gov

4^th place

5doi.org

2^nd place

2web.archive.org

1^st place

2handle.net

102^nd place

76^th place

2worldcat.org

5^th place

1tga.gov.au

3,984^th place

2,622^nd place

1canada.ca

1,712^th place

1,063^rd place

1medicines.org.uk

3,823^rd place

2,387^th place

1europa.eu

68^th place

117^th place

1fda.gov

447^th place

338^th place

1thrombosiscanada.ca

low place

1ama-assn.org

3,257^th place

3,398^th place

ama-assn.org

"Idarucizumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association. Archived from the original (PDF) on 2015-06-27.

canada.ca

"Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.

doi.org

Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. (August 2015). "Idarucizumab for Dabigatran Reversal". The New England Journal of Medicine. 373 (6): 511–520. doi:10.1056/NEJMoa1502000. PMID 26095746.
Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI (December 2015). "Idarucizumab: The Antidote for Reversal of Dabigatran". Circulation. 132 (25): 2412–2422. doi:10.1161/CIRCULATIONAHA.115.019628. PMID 26700008.
Thibault N, Morrill AM, Willett KC (2018). "Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review". American Journal of Therapeutics. 25 (3): e333 – e338. doi:10.1097/MJT.0000000000000460. PMID 27175894.
van der Horst SF, Martens ES, den Exter PL, Bos MH, van Mens TE, Huisman MV, et al. (August 2023). "Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes". Thrombosis Research. 228: 21–32. doi:10.1016/j.thromres.2023.05.020. PMID 37267671.
Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. (January 2024). "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Journal of the American College of Cardiology. 83 (1): 109–279. doi:10.1016/j.jacc.2023.08.017. PMC 11104284. PMID 38043043.

europa.eu

ema.europa.eu

"Praxbind EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 16 October 2020.

fda.gov

"FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 2015-10-17. Retrieved 2015-10-17.

handle.net

hdl.handle.net

World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information. 28 (1): 90–91. hdl:10665/331151.
World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3): 544. hdl:10665/331020.

medicines.org.uk

"Praxbind 2.5 g/50 mL solution for injection/infusion - Summary of Product Characteristics (SmPC)". (emc). 1 July 2022. Retrieved 1 July 2022.

nih.gov

pubmed.ncbi.nlm.nih.gov

Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. (August 2015). "Idarucizumab for Dabigatran Reversal". The New England Journal of Medicine. 373 (6): 511–520. doi:10.1056/NEJMoa1502000. PMID 26095746.
Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI (December 2015). "Idarucizumab: The Antidote for Reversal of Dabigatran". Circulation. 132 (25): 2412–2422. doi:10.1161/CIRCULATIONAHA.115.019628. PMID 26700008.
Thibault N, Morrill AM, Willett KC (2018). "Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review". American Journal of Therapeutics. 25 (3): e333 – e338. doi:10.1097/MJT.0000000000000460. PMID 27175894.
van der Horst SF, Martens ES, den Exter PL, Bos MH, van Mens TE, Huisman MV, et al. (August 2023). "Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes". Thrombosis Research. 228: 21–32. doi:10.1016/j.thromres.2023.05.020. PMID 37267671.
Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. (January 2024). "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Journal of the American College of Cardiology. 83 (1): 109–279. doi:10.1016/j.jacc.2023.08.017. PMC 11104284. PMID 38043043.

dailymed.nlm.nih.gov

"Praxbind- idarucizumab injection". DailyMed. U.S. National Library of Medicine. 1 December 2019. Retrieved 19 August 2020.
"DailyMed - PRAXBIND- idarucizumab injection". dailymed.nlm.nih.gov. Retrieved 2024-05-01.

ncbi.nlm.nih.gov

Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. (January 2024). "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Journal of the American College of Cardiology. 83 (1): 109–279. doi:10.1016/j.jacc.2023.08.017. PMC 11104284. PMID 38043043.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

thrombosiscanada.ca

"Thrombosis Canada". thrombosiscanada.ca. Retrieved 2024-05-01.

web.archive.org

"FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 2015-10-17. Retrieved 2015-10-17.
"Idarucizumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association. Archived from the original (PDF) on 2015-06-27.

worldcat.org

Briggs GG, Freeman RK, Towers CV, Forinash AB (2017). Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk (11th ed.). Philadelphia, PA: Wolters Kluwer. ISBN 978-1-4963-4962-0. OCLC 951509534.

search.worldcat.org

Briggs GG, Freeman RK, Towers CV, Forinash AB (2017). Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk (11th ed.). Philadelphia, PA: Wolters Kluwer. ISBN 978-1-4963-4962-0. OCLC 951509534.